NeoGenomics names Jack Kenny to board, filling seat left by Alison Hannah
NeoGenomics said director Alison L. Hannah, MD, resigned effective December 31, 2025, and the Board appointed John P. "Jack" Kenny to fill the vacancy effective January 1, 2026. Kenny will serve until the 2026 annual meeting and will receive independent director compensation under the company's existing program. The change affects board composition but the filing does not report any financial figures.
Key points
- Dr. Alison L. Hannah's resignation as director is effective December 31, 2025; the Board accepted it on December 23, 2025.
- Jack Kenny was appointed to the Board effective January 1, 2026, to fill the vacancy.
- Kenny previously served as President, Chief Executive Officer and Board Director of Meridian Bioscience, per the press release (Exhibit 99.1, dated December 29, 2025).
- Kenny will serve until the 2026 annual meeting, and the filing reports no related-party transactions requiring disclosure under Item 404(a).
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 30, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.